Overview on the Link Between the Complement System and Auto-Immune Articular and Pulmonary Disease

References

• Holers VM, Banda NK. Complement in the initiation and evolution of rheumatoid arthritis. Front Immunol. 2018;9:1057. doi:10.3389/fimmu.2018.01057
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ballanti E, Triggianese P, Perricone R. Vasculitides and the complement system: a comprehensive review. Clin Rev Allergy Immunol. 2015;49:333–346. doi:10.1007/s12016-014-8453-8
   PubMed Web of Science ®Google Scholar
• Lay WH, Nussenzweig V. Receptors for complement of leukocytes. J Exp Med. 1968;128(5):991–1009. doi:10.1084/jem.128.5.991
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Greco E, et al Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–491. doi:10.1007/s12026-013-8422-y
   PubMed Web of Science ®Google Scholar
• Bemis EA, Norris JM, Seifert J, et al Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol Immunol. 2019;112:256–265. doi:10.1016/j.molimm.2019.05.012
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140–1144. doi:10.1056/NEJM200104123441506
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Triggianese P, Ballanti E, Perricone C, Perricone R, Chimenti MS. Complement, infection, and autoimmunity. Curr Opin Rheumatol. 2019;31(5):532–541. doi:10.1097/BOR.0000000000000633
   PubMed Web of Science ®Google Scholar
• Jia C, Tan Y, Zhao M. The complement system and autoimmune diseases. Chronic Dis Transl Med. 2022;8(3):184–190. doi:10.1002/cdt3.24
   PubMedGoogle Scholar
• Yuan ZC, Xu WD, Lan YY, et al Association of MBL2 gene polymorphisms and systemic lupus erythematosus susceptibility: a meta-analysis. Int J Rheum Dis. 2021;24(2):147–158. doi:10.1111/1756-185X.14017
   PubMed Web of Science ®Google Scholar
• Mahto H, Pati A, Sahu SK, Sharma HP, Padhi A, Panda AK. Association of MBL-2 gene polymorphisms with systemic lupus erythematosus: an updated meta-analysis and trial sequential analysis. Lupus. 2020;29(10):1227–1237. doi:10.1177/0961203320939156
   PubMed Web of Science ®Google Scholar
• Gropp K, Weber N, Reuter M, et al β2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118(10):2774–2783. doi:10.1182/blood-2011-02-339564
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Braunstein EM, Yuan X, et al Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135:239!251. doi:10.1182/blood.2019003863
   PubMed Web of Science ®Google Scholar
• Sprott H, Müller-Ladner U, Distler O, et al Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol. 2000;27(2):402–404.
   PubMed Web of Science ®Google Scholar
• Devresse A, Aydin S, Le Quintrec M, et al Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine. 2016;95(30):e4459. doi:10.1097/MD.0000000000004459
   PubMed Web of Science ®Google Scholar
• Batal I, Domsic RT, Shafer A, et al Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40(3):332–340. doi:10.1016/j.humpath.2008.08.001
   PubMed Web of Science ®Google Scholar
• Okrój M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016;18(1):267. doi:10.1186/s13075-016-1168-x
   PubMedGoogle Scholar
• Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjögren’s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018;36(3):198–209.
   PubMed Web of Science ®Google Scholar
• Lundtoft C, Sjöwall C, Rantapää-Dahlqvist S, et al Strong association of combined genetic deficiencies in the classical complement pathway with risk of systemic lupus erythematosus and primary Sjögren’s syndrome. Arthritis Rheumatol. 2022;74(11):1842–1850. doi:10.1002/art.42270
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Perricone C, Graceffa D, et al Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30(1):23–30.
   PubMed Web of Science ®Google Scholar
• Partsch G, Bauer K, Bröll H, Petera P, Dunky A, Merétey K. Complement C3 cleavage product in synovial fluids detected by immunofixation. Z Rheumatol. 1991;50(2):82–85.
   PubMed Web of Science ®Google Scholar
• Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18:226. doi:10.1186/s13075-016-1116-9
   PubMed Web of Science ®Google Scholar
• Trouw LA, Haisma EM, Levarht EW, et al Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009;60(7):1923–1931. doi:10.1002/art.24622
   PubMed Web of Science ®Google Scholar
• Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi:10.1016/j.smim.2019.101339
   PubMed Web of Science ®Google Scholar
• Sakiyama H, Inaba N, Toyoguchi T, et al Immunolocalization of complement C1s and matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase) in the primary ossification center of the human femur. Cell Tissue Res. 1994;277(2):239–245.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Sakiyama H, Tsuchida T, et al Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody. Ann Rheum Dis. 1999;58(3):175–181. doi:10.1136/ard.58.3.175
   PubMed Web of Science ®Google Scholar
• Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol. 2015;194(8):3664–3674. doi:10.4049/jimmunol.1402334
   PubMed Web of Science ®Google Scholar
• Harre U, Georgess D, Bang H, et al Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791–1802. doi:10.1172/JCI60975
   PubMed Web of Science ®Google Scholar
• Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17(1):60–75. doi:10.1038/nri.2016.124
   PubMed Web of Science ®Google Scholar
• Mizuno M. A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. Curr Med Chem. 2006;13(14):1707–1717. doi:10.2174/092986706777441959
   PubMed Web of Science ®Google Scholar
• D’Cruz D, Taylor J, Ahmed T, Asherson R, Khamashta M, Hughes GR. Complement factor 2 deficiency: a clinical and serological family study. Ann Rheum Dis. 1992;51(11):1254–1256. doi:10.1136/ard.51.11.1254
   PubMed Web of Science ®Google Scholar
• Trouw LA, Daha N, Kurreeman FA, et al Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin Exp Immunol. 2013;173(1):76–83. doi:10.1111/cei.12097
   PubMed Web of Science ®Google Scholar
• Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum. 2006;54(4):1143–1150. doi:10.1002/art.21729
   PubMedGoogle Scholar
• Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis. 1989;48(4):302–306. doi:10.1136/ard.48.4.302
   PubMed Web of Science ®Google Scholar
• Doherty M, Richards N, Hornby J, Powell R. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. Ann Rheum Dis. 1988;47(3):190–197. doi:10.1136/ard.47.3.190
   PubMed Web of Science ®Google Scholar
• Nguyen THP, Hokstad I, Fagerland MW, et al Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis. PLoS One. 2022;17(2):e0264628. doi:10.1371/journal.pone.0264628
   PubMed Web of Science ®Google Scholar
• Volanakis JE. Complement activation by C-reactive protein complexes. Ann N Y Acad Sci. 1982;389:235–250. doi:10.1111/j.1749-6632.1982.tb22140.x
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157(1):473–479. doi:10.4049/jimmunol.157.1.473
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Niessen HW, Wolbink GJ, et al C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95(1):97–103. doi:10.1161/01.CIR.95.1.97
   PubMed Web of Science ®Google Scholar
• Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum. 2001;44(5):997–1002. doi:10.1002/1529-0131(200105)44:5<997::AID-ANR178>3.0.CO;2-C
   PubMedGoogle Scholar
• Conigliaro P, D’Antonio A, Pinto S, et al Autoimmune thyroid disorders and rheumatoid arthritis: a bidirectional interplay. Autoimmun Rev. 2020;19(6):102529. doi:10.1016/j.autrev.2020.102529
   PubMed Web of Science ®Google Scholar
• Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722–727. doi:10.1136/ard.62.8.722
   PubMed Web of Science ®Google Scholar
• Fazeli MS, Khaychuk V, Wittstock K, et al Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. Clin Exp Rheumatol. 2021;39(5):1108–1118. doi:10.55563/clinexprheumatol/h9tc57
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med. 2019;6:238. doi:10.3389/fmed.2019.00238
   PubMed Web of Science ®Google Scholar
• Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4(5):443–448. doi:10.1513/pats.200703-045MS
   PubMedGoogle Scholar
• Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33(4):221–227. doi:10.1080/03009740410005845
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, et al Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–1591. doi:10.1002/art.27405
   PubMed Web of Science ®Google Scholar
• Kim D, Cho SK, Choi CB, et al Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatol Int. 2017;37(10):1735–1745. doi:10.1007/s00296-017-3781-7
   PubMed Web of Science ®Google Scholar
• Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(6):247–267. doi:10.1177/1759720X15612250
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41(5):817–822. doi:10.1002/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S
   PubMedGoogle Scholar
• Kelly CA, Saravanan V, Nisar M, et al; British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology. 2014;53(9):1676–1682. doi:10.1093/rheumatology/keu165
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, et al Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–166. doi:10.1001/archinternmed.2007.59
   PubMedGoogle Scholar
• Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine. 2019;98(38):e17088. doi:10.1097/MD.0000000000017088
   PubMed Web of Science ®Google Scholar
• Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology. 2013;52(1):99–110. doi:10.1093/rheumatology/kes262
   PubMed Web of Science ®Google Scholar
• Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int. 2012;32(3):669–673. doi:10.1007/s00296-010-1665-1
   PubMed Web of Science ®Google Scholar
• Yunt ZX, Chung JH, Hobbs S, et al High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival. Respir Med. 2017;126:100–104. doi:10.1016/j.rmed.2017.03.027
   PubMed Web of Science ®Google Scholar
• Caples SM, Utz JP, Allen MS, Ryu JH. Thoracic surgical procedures in patients with rheumatoid arthritis. J Rheumatol. 2004;31(11):2136–2141.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328. doi:10.1183/09031936.00092309
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kim JS, Newell JD, et al Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81–89. doi:10.1148/radiol.2321030174
   PubMed Web of Science ®Google Scholar
• Assayag D, Elicker BM, Urbania TH, et al Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270(2):583–588. doi:10.1148/radiol.13130187
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Ryu JH, Tazelaar HD, et al Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107(8):1247–1252. doi:10.1016/j.rmed.2013.05.002
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Takayanagi N, Sugiura H, et al Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–1417. doi:10.1183/09031936.00019210
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL
   PubMed Web of Science ®Google Scholar
• Lynch DA, Godwin JD, Safrin S, et al; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488–493. doi:10.1164/rccm.200412-1756OC
   PubMed Web of Science ®Google Scholar
• Sumikawa H, Johkoh T, Colby TV, et al Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008;177(4):433–439. doi:10.1164/rccm.200611-1696OC
   PubMed Web of Science ®Google Scholar
• Yagihashi K, Huckleberry J, Colby TV, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J. 2016;47(4):1189–1197. doi:10.1183/13993003.01680-2015
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Thwaite EL, Kazerooni EA, et al Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58(2):143–148. doi:10.1136/thorax.58.2.143
   PubMed Web of Science ®Google Scholar
• Yıldırım F, Türk M, Bitik B, et al Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. Kaohsiung J Med Sci. 2019;35(6):365–372. doi:10.1002/kjm2.12066
   PubMed Web of Science ®Google Scholar
• Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. BMC Pulm Med. 2016;16(1):107. doi:10.1186/s12890-016-0269-2
   PubMedGoogle Scholar
• Shigemitsu H, Azuma A. Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum. Curr Opin Pulm Med. 2011;17(5):303–307. doi:10.1097/MCP.0b013e3283486d52
   PubMed Web of Science ®Google Scholar
• Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–114. doi:10.1183/09059180.00003214
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Jayaraman A, Reinhardt C, Campbell JD, Bosmann M. A single-cell lung atlas of complement genes identifies the mesothelium and epithelium as prominent sources of extrahepatic complement proteins. Mucosal Immunol. 2022;15(5):927–939. doi:10.1038/s41385-022-00534-7
   PubMed Web of Science ®Google Scholar
• Pandya PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol. 2014;51(4):467–473. doi:10.1165/rcmb.2013-0485TR
   PubMed Web of Science ®Google Scholar
• Kulkarni HS, Liszewski MK, Brody SL, Atkinson JP. The complement system in the airway epithelium: an overlooked host defense mechanism and therapeutic target? J Allergy Clin Immunol. 2018;141(5):1582–1586.e1. doi:10.1016/j.jaci.2017.11.046
   PubMed Web of Science ®Google Scholar
• Andre GO, Converso TR, Politano WR, et al Role of Streptococcus pneumoniae proteins in evasion of complement-mediated immunity. Front Microbiol. 2017;8:224. doi:10.3389/fmicb.2017.00224
   PubMed Web of Science ®Google Scholar
• Ackerman SK, Friend PS, Hoidal JR, Douglas SD. Production of C2 by human alveolar macrophages. Immunology. 1978;35(2):369–372.
   PubMed Web of Science ®Google Scholar
• Angelidis I, Simon LM, Fernandez IE, et al An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat Commun. 2019;10(1):963. doi:10.1038/s41467-019-08831-9
   PubMedGoogle Scholar
• Travaglini KJ, Nabhan AN, Penland L, et al A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature. 2020;587(7835):619–625. doi:10.1038/s41586-020-2922-4
   PubMed Web of Science ®Google Scholar
• Gaurav R, Mikuls TR, Thiele GM, et al High-throughput analysis of lung immune cells in a combined murine model of agriculture dust-triggered airway inflammation with rheumatoid arthritis. PLoS One. 2021;16(2):e0240707. doi:10.1371/journal.pone.0240707
   PubMed Web of Science ®Google Scholar
• Mangogna A, Varghese PM, Agostinis C, et al Prognostic value of complement properdin in cancer. Front Immunol. 2021;11:614980. doi:10.3389/fimmu.2020.614980
   PubMed Web of Science ®Google Scholar
• Luo L, Li X, Hu X, et al Anaphylatoxins enhance recruitment of nonclassical monocytes via chemokines produced by pleural mesothelial cells in tuberculous pleural effusion. Am J Respir Cell Mol Biol. 2019;60(4):454–464. doi:10.1165/rcmb.2018-0075OC
   PubMed Web of Science ®Google Scholar
• Gu H, Mickler EA, Cummings OW, et al Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J. 2014;28(10):4223–4234. doi:10.1096/fj.13-247650
   PubMed Web of Science ®Google Scholar
• Drouin SM, Kildsgaard J, Haviland J, et al Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol. 2001;166(3):2025–2032. doi:10.4049/jimmunol.166.3.2025
   PubMed Web of Science ®Google Scholar
• Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol. 2012;946:147–159.
   PubMed Web of Science ®Google Scholar
• Bosmann M. Complement control for COVID-19. Sci Immunol. 2021;6(59):eabj1014. doi:10.1126/sciimmunol.abj1014
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Perricone R. COVID-19: disCOVering the role of complement system. Clin Exp Rheumatol. 2020;38(4):587–591.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Chen YF, Robbins RA, Gadek JE, Crystal RG. Fibronectin mediates cell attachment to C1q: a mechanism for the localization of fibrosis in inflammatory disease. Clin Exp Immunol. 1983;54(1):239–247.
   PubMed Web of Science ®Google Scholar
• Phan SH, Thrall RS. Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor. Am J Pathol. 1982;107(1):25–28.
   PubMed Web of Science ®Google Scholar
• Addis-Lieser E, Köhl J, Chiaramonte MG. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J Immunol. 2005;175(3):1894–1902. doi:10.4049/jimmunol.175.3.1894
   PubMed Web of Science ®Google Scholar
• Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE. Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med. 1978;298(7):353–357. doi:10.1056/NEJM197802162980701
   PubMed Web of Science ®Google Scholar
• Haslam PL, Allan F, Watling AF, Barrett C, Morris L, Turner-Warwick M. Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis). Clin Exp Immunol. 1982;49(1):59–66.
   PubMed Web of Science ®Google Scholar
• Jansen HM, Schutte AJ, Elema JD, et al Local immune complexes and inflammatory response in patients with chronic interstitial pulmonary disorders associated with collagen vascular diseases. Clin Exp Immunol. 1984;56(2):311–320.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Janssen WJ, Terada M. Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med. 2012;106(12):1800–1803. doi:10.1016/j.rmed.2012.08.020
   PubMed Web of Science ®Google Scholar
• Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun. 2010;2(2):114–122. doi:10.1159/000228159
   PubMed Web of Science ®Google Scholar
• Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta. 2002;1572(2–3):401–413. doi:10.1016/S0304-4165(02)00321-5
   PubMed Web of Science ®Google Scholar
• Arney V. The deficiency of serum mannose binding lectin in early onset idiopathic pulmonary fibrosis and familial cases. J Clin Cell Immunol. 2013;3:127.
   Google Scholar
• Vogt S, Trendelenburg M, Tamm M, Stolz D, Hostettler KE, Osthoff M. Local and systemic concentrations of pattern recognition receptors of the lectin pathway of complement in a cohort of patients with interstitial lung diseases. Front Immunol. 2020;11:562564. doi:10.3389/fimmu.2020.562564
   PubMed Web of Science ®Google Scholar
• Osthoff M, Ngian GS, Dean MM, et al Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. Arthritis Res Ther. 2014;16(6):480. doi:10.1186/s13075-014-0480-6
   PubMed Web of Science ®Google Scholar
• Pellicano C, Miglionico M, Romaggioli L, et al Increased complement activation in systemic sclerosis patients with skin and lung fibrosis. J Pers Med. 2022;12(2):284. doi:10.3390/jpm12020284
   PubMed Web of Science ®Google Scholar
• Okamoto T, Mathai SK, Hennessy CE, et al The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018;315(1):L1–L10. doi:10.1152/ajplung.00395.2017
   PubMed Web of Science ®Google Scholar
• Gu H, Fisher AJ, Mickler EA, et al Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. FASEB J. 2016;30(6):2336–2350. doi:10.1096/fj.201500044
   PubMed Web of Science ®Google Scholar
• Korczowska I. Rheumatoid arthritis susceptibility genes: an overview. World J Orthop. 2014;5(4):544–549. doi:10.5312/wjo.v5.i4.544
   PubMedGoogle Scholar
• Sena L, Oliveira-Toré CF, Skare T, de Messias-Reason IJ, Andrade FA. C3 gene functional polymorphisms and C3 serum levels in patients with rheumatoid arthritis. Immunol Invest. 2021;50(8):1027–1041. doi:10.1080/08820139.2020.1800726
   PubMed Web of Science ®Google Scholar
• Banda NK, Deane KD, Bemis EA, et al Analysis of complement gene expression, clinical associations, and biodistribution of complement proteins in the synovium of early rheumatoid arthritis patients reveals unique pathophysiologic features. J Immunol. 2022;208(11):2482–2496. doi:10.4049/jimmunol.2101170
   PubMed Web of Science ®Google Scholar
• Neumann E, Barnum SR, Tarner IH, et al Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002;46(4):934–945. doi:10.1002/art.10183
   PubMed Web of Science ®Google Scholar
• Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 1991;34(12):1531–1537. doi:10.1002/art.1780341209
   PubMedGoogle Scholar
• Konttinen YT, Ceponis A, Meri S, et al Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis. 1996;55(12):888–894. doi:10.1136/ard.55.12.888
   PubMed Web of Science ®Google Scholar
• Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a therapeutic target in systemic autoimmune diseases. Cells. 2021;10(1):148. doi:10.3390/cells10010148
   PubMed Web of Science ®Google Scholar
• Banda NK, Kraus D, Vondracek A, et al Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 2002;46(11):3065–3075. doi:10.1002/art.10591
   PubMedGoogle Scholar
• Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol. 2002;169(1):454–459. doi:10.4049/jimmunol.169.1.454
   PubMed Web of Science ®Google Scholar
• Matsumoto I, Maccioni M, Lee DM, et al How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3(4):360–365. doi:10.1038/ni772
   PubMed Web of Science ®Google Scholar
• Monach PA, Verschoor A, Jacobs JP, et al Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. Arthritis Rheum. 2007;56(9):2968–2974. doi:10.1002/art.22859
   PubMedGoogle Scholar
• Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538–547. doi:10.1038/nrrheum.2017.125
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986;29(6):715–721. doi:10.1002/art.1780290603
   PubMedGoogle Scholar
• Moffat GJ, Lappin D, Birnie GD, Whaley K. Complement biosynthesis in human synovial tissue. Clin Exp Immunol. 1989;78(1):54–60.
   PubMed Web of Science ®Google Scholar
• Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol. 1999;36(13–14):905–914. doi:10.1016/S0161-5890(99)00113-3
   PubMed Web of Science ®Google Scholar
• Friščić J, Böttcher M, Reinwald C, et al The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. Immunity. 2021;54(5):1002–1021.e10. doi:10.1016/j.immuni.2021.03.003
   PubMed Web of Science ®Google Scholar
• Kolev M, Dimeloe S, Le Friec G, et al Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity. 2015;42(6):1033–1047. doi:10.1016/j.immuni.2015.05.024
   PubMed Web of Science ®Google Scholar
• Laumonnier Y, Karsten CM, Köhl J. Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol. 2017;89:44–58. doi:10.1016/j.molimm.2017.05.019
   PubMed Web of Science ®Google Scholar
• Liszewski MK, Kolev M, Le Friec G, et al Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39(6):1143–1157. doi:10.1016/j.immuni.2013.10.018
   PubMed Web of Science ®Google Scholar
• Arbore G, West EE, Spolski R, et al T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science. 2016;352(6292):aad1210. doi:10.1126/science.aad1210
   PubMed Web of Science ®Google Scholar
• Cambré I, Gaublomme D, Burssens A, et al Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun. 2018;9(1):4613. doi:10.1038/s41467-018-06933-4
   PubMed Web of Science ®Google Scholar
• Cambré I, Gaublomme D, Schryvers N, et al Running promotes chronicity of arthritis by local modulation of complement activators and impairing T regulatory feedback loops. Ann Rheum Dis. 2019;78(6):787–795. doi:10.1136/annrheumdis-2018-214627
   PubMed Web of Science ®Google Scholar
• Marchi LF, Paoliello-Paschoalato AB, Oliveira RDR, et al Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with infliximab and methotrexate. Rheumatol Int. 2018;38(6):1043–1052. doi:10.1007/s00296-018-3997-1
   PubMed Web of Science ®Google Scholar
• Cutolo M, Seriolo B, Pizzorni C, Craviotto C, Sulli A. Methotrexate in psoriatic arthritis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S76–80.
   PubMed Web of Science ®Google Scholar
• Belinsky GS, Parke AL, Huang Q, et al The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007;97(2):582–594. doi:10.1093/toxsci/kfm067
   PubMed Web of Science ®Google Scholar
• Di Muzio G, Perricone C, Ballanti E, et al Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol. 2011;24(2):357–366. doi:10.1177/039463201102400209
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Di Muzio G, et al Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10(10):617–623. doi:10.1016/j.autrev.2011.04.012
   PubMed Web of Science ®Google Scholar
• Familian A, Voskuyl AE, van Mierlo GJ, et al Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(7):1003–1008. doi:10.1136/ard.2004.029124
   PubMed Web of Science ®Google Scholar
• Hokstad I, Deyab G, Wang Fagerland M, et al Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: an observational study. PLoS One. 2019;14(7):e0220079. doi:10.1371/journal.pone.0220079
   PubMed Web of Science ®Google Scholar
• Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3(5):333–340.
   PubMed Web of Science ®Google Scholar
• Perissutti S, Tedesco F. Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells. Int J Clin Lab Res. 1994;24(1):45–48. doi:10.1007/BF02592409
   PubMedGoogle Scholar
• Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42(1–3):23–30. doi:10.1016/S0162-3109(99)00007-7
   PubMed Web of Science ®Google Scholar
• Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M. Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study. PLoS One. 2016;11(9):e0162316. doi:10.1371/journal.pone.0162316
   PubMed Web of Science ®Google Scholar
• Romano C, Del Mastro A, Sellitto A, Solaro E, Esposito S, Cuomo G. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. Clin Rheumatol. 2018;37(6):1695–1700. doi:10.1007/s10067-018-3992-7
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Triggianese P, Chimenti MS, Lucchetti R, Kroegler B, Perricone R. Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab. J Int Med Res. 2016;44(1 suppl):53–57. doi:10.1177/0300060515593240
   PubMedGoogle Scholar
• Blom AM, Nandakumar KS, Holmdahl R. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann Rheum Dis. 2009;68(1):136–142. doi:10.1136/ard.2007.085753
   PubMed Web of Science ®Google Scholar
• Hornum L, Hansen AJ, Tornehave D, et al C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid. PLoS One. 2017;12(12):e0189017. doi:10.1371/journal.pone.0189017
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, Dinant H, et al Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology. 2007;46(12):1773–1778. doi:10.1093/rheumatology/kem222
   PubMed Web of Science ®Google Scholar
• Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148(3):313–321. doi:10.1016/j.clim.2013.02.014
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–559. doi:10.1056/NEJMoa031688
   PubMed Web of Science ®Google Scholar
• Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc. 2004;1:239–246. doi:10.1513/pats.200402-005MS
   PubMedGoogle Scholar
• Gregory AD, Kliment CR, Metz HE, et al Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis. J Leukoc Biol. 2015;98(2):143–152. doi:10.1189/jlb.3HI1014-493R
   PubMed Web of Science ®Google Scholar
• Hammerschmidt DE, White JG, Craddock PR, Jacob HS. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest. 1979;63(4):798–803. doi:10.1172/JCI109365
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19. doi:10.1016/j.ejps.2014.02.014
   PubMed Web of Science ®Google Scholar
• Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, et al Role and new insights of pirfenidone in fibrotic diseases. Int J Med Sci. 2015;12(11):840–847. doi:10.7150/ijms.11579
   PubMed Web of Science ®Google Scholar
• Langer HF, Chung KJ, Orlova VV, et al Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010;116:4395–4403. doi:10.1182/blood-2010-01-261503
   PubMed Web of Science ®Google Scholar
• Roth GJ, Binder R, Colbatzky F, et al Nintedanib: from discovery to the clinic. J Med Chem. 2015;58(3):1053–1063. doi:10.1021/jm501562a
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–1445. doi:10.1183/09031936.00174914
   PubMed Web of Science ®Google Scholar
• Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–852. doi:10.1146/annurev.immunol.23.021704.115835
   PubMed Web of Science ®Google Scholar
• Bejan-Angoulvant T, Naccache JM, Caille A, et al Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): a double-blind placebo-controlled randomized trial. Respir Med Res. 2020;78:100770. doi:10.1016/j.resmer.2020.100770
   PubMedGoogle Scholar
• Bieber A, Markovits D, Toledano K, et al Hypocomplementemia during tocilizumab treatment: long-term follow-up results. Medicine. 2022;101(24):e29528. doi:10.1097/MD.0000000000029528
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Teramoto S, Fukuchi Y, Uejima Y, Shu CY, Orimo H. Superoxide anion formation and glutathione metabolism of blood in patients with idiopathic pulmonary fibrosis. Biochem Mol Med. 1995;55(1):66–70. doi:10.1006/bmme.1995.1033
   PubMedGoogle Scholar
• Perricone C, De Carolis C, Giacomelli R, et al Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol. 2011;24(1):63–68. doi:10.1177/039463201102400108
   PubMed Web of Science ®Google Scholar
• Bianchi L, Chimenti MS, Giunta A. Treatment of Hailey-Hailey disease with topical calcitriol. J Am Acad Dermatol. 2004;51(3):475–476. doi:10.1016/j.jaad.2003.10.668
   PubMed Web of Science ®Google Scholar
• Haapasalo K, Meri S. Regulation of the complement system by pentraxins. Front Immunol. 2019;10:1750. doi:10.3389/fimmu.2019.01750
   PubMed Web of Science ®Google Scholar
• Yang Z, Nicholson SE, Cancio TS, Cancio LC, Li Y. Complement as a vital nexus of the pathobiological connectome for acute respiratory distress syndrome: an emerging therapeutic target. Front Immunol. 2023;14:1100461. doi:10.3389/fimmu.2023.1100461
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. 2013;2013:379040. doi:10.1155/2013/379040
   PubMedGoogle Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2018;319(22):2299–2307. doi:10.1001/jama.2018.6129
   PubMed Web of Science ®Google Scholar
• Hench PS, Kendall EC, Slocumb CH. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc. 1949;24:181–197.
   PubMed Web of Science ®Google Scholar
• Ishmael FT, Fang X, Galdiero MR, et al Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol. 2008;180(12):8342–8353. doi:10.4049/jimmunol.180.12.8342
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc. 2004;1:222–230. doi:10.1513/pats.200402-018MS
   PubMedGoogle Scholar
• Mohammad AJ, Mortensen KH, Babar J, et al Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol. 2017;44(10):1458–1467. doi:10.3899/jrheum.161224
   PubMed Web of Science ®Google Scholar
• Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91. doi:10.1016/j.rmed.2018.12.015
   PubMed Web of Science ®Google Scholar
• Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24(1):119–132. doi:10.3109/01902149809046058
   PubMed Web of Science ®Google Scholar
• Xiong Z, Wang Q, Li W, et al Platelet-derived growth factor-D activates complement system to propagate macrophage polarization and neovascularization. Front Cell Dev Biol. 2021;9:686886. doi:10.3389/fcell.2021.686886
   PubMed Web of Science ®Google Scholar
• Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016;10(12):1247–1254. doi:10.1080/17476348.2016.1249854
   PubMed Web of Science ®Google Scholar
• Omori T, Oguchi Y, Machida T, et al Evidence for activation of lectin and classical pathway complement components in aqueous humor of neovascular age-related macular degeneration. Ophthalmic Res. 2019;63:252–258. doi:10.1159/000503258
   PubMed Web of Science ®Google Scholar
• Kozhevnikova OS, Fursova AZ, Derbeneva AS, et al Association between polymorphisms in CFH, ARMS2, CFI, and C3 genes and response to anti-VEGF treatment in neovascular age-related macular degeneration. Biomedicines. 2022;10(7):1658. doi:10.3390/biomedicines10071658
   PubMed Web of Science ®Google Scholar
• Yu WK, Chen WC, Su VY, et al Nintedanib inhibits endothelial mesenchymal transition in bleomycin-induced pulmonary fibrosis via focal adhesion kinase activity reduction. Int J Mol Sci. 2022;23(15):8193. doi:10.3390/ijms23158193
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720X221116408. doi:10.1177/1759720X221116408
   PubMed Web of Science ®Google Scholar
• Fui A, Bergantini L, Selvi E, et al Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. 2020;50(3):330–336. doi:10.1111/imj.14306
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–2743. doi:10.1182/blood-2003-06-2031
   PubMed Web of Science ®Google Scholar
• Felberg A, Taszner M, Urban A, et al Monitoring of the complement system status in patients with b-cell malignancies treated with rituximab. Front Immunol. 2020;11:584509. doi:10.3389/fimmu.2020.584509
   PubMed Web of Science ®Google Scholar
• Park CS, Chung SW, Ki SY, et al Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1162–1168. doi:10.1164/ajrccm.162.3.9906007
   PubMed Web of Science ®Google Scholar
• Mozaffarian A, Brewer AW, Trueblood ES, et al Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008;181(10):7243–7253. doi:10.4049/jimmunol.181.10.7243
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.govt. Available from: https://clinicaltrials.gov/ct2/show/study/NCT05181397.
   Google Scholar
• Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22(12):6211. doi:10.3390/ijms22126211
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811. doi:10.1038/nrd3810
   PubMed Web of Science ®Google Scholar
• Janssen-Heininger Y, Reynaert NL, van der Vliet A, Anathy V. Endoplasmic reticulum stress and glutathione therapeutics in chronic lung diseases. Redox Biol. 2020;33:101516. doi:10.1016/j.redox.2020.101516
   PubMed Web of Science ®Google Scholar
• Pilling D, Roife D, Wang M, et al Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007;179(6):4035–4044. doi:10.4049/jimmunol.179.6.4035
   PubMed Web of Science ®Google Scholar
• Salhi S, Ribes D, Faguer S. Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy. Clin Kidney J. 2020;14(4):1275–1276. doi:10.1093/ckj/sfaa101
   PubMed Web of Science ®Google Scholar
• Huizenga N, Zonozi R, Rosenthal J, Laliberte K, Niles JL, Cortazar FB. Treatment of aggressive antineutrophil cytoplasmic antibody-associated vasculitis with eculizumab. Kidney Int Rep. 2019;5(4):542–545. doi:10.1016/j.ekir.2019.11.021
   PubMed Web of Science ®Google Scholar
• Flohé L. Glutathione peroxidase. Basic Life Sci. 1988;49:663–668. doi:10.1007/978-1-4684-5568-7_104
   PubMedGoogle Scholar